SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021.
Anthony O EtyangIfedayo M O AdetifaRichard OmoreThomas MisoreAbdhalah K ZirabaMaurine A Ng'odaEvelyn N GitauJohn GitongaDaisy MugoBernadette KutimaHenry K KaranjaMonica ToroitichJames NyagwangeJames TujuPerpetual WanjikuRashid AmanPatrick AmothMercy MwangangiKadondi KaseraWangari Ng'ang'aDonald AkechAntipa SigilaiBoniface KariaAngela KaraniShirine VollerCharles N AgotiLynette I Ochola-OyierMark OtiendeChristian BottomleyNyaguara O AmekSophie UyogaKatherine E GallagherE Wangeci KaguciaDickens Otieno OnyangoBenjamin TsofaJoseph MwangangiEric MaithaEdwine W BarasaPhilip BejonGeorge M WarimweJ Anthony G ScottAmbrose AgweyuPublished in: PLOS global public health (2022)
By May 2021 in three broadly representative populations of unvaccinated individuals in Kenya, seroprevalence of anti-SARS-CoV-2 IgG was 25-50%. There was wide variation in cumulative incidence by location and age.